Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177367 | 0.93 | NSD2 (0.36) | NSD2ALDH1A1EGFRLMNAMAPT | |
| SCHEMBL351106 | 0.90 | MAPK1 (0.34) | NSD2ALDH1A1EGFRLMNAMAPT | |
| SCHEMBL350079 | 0.90 | NSD2 (0.32) | NSD2ALDH1A1EGFRLMNAMAPT | |
| SCHEMBL24535255 | 0.83 | — | — | |
| SCHEMBL352304 | 0.80 | HTR7 (0.36) | ALDH1A1MAPTTDP1PDK2 | |
| SCHEMBL352021 | 0.78 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL352694 | 0.77 | L3MBTL1 (0.45) | NSD2ALDH1A1EGFRLMNAMAPT | |
| SCHEMBL10177371 | 0.77 | MEN1 (0.31) | — | |
| SCHEMBL350457 | 0.77 | CA1 (0.38) | — | |
| SCHEMBL351419 | 0.76 | KDM4E (0.33) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | NSD2 1155/4885ALDH1A1 4611/4885EGFR 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.